The Alexandria Center for Life Science currently houses some of the most ambitious biotech startups in New York, not to mention some outposts for pharma companies like Roche and Pfizer. Not bad for something that, as Alexandria Real Estate Equities CEO Joel Marcus said, “was a contaminated laundry site” just a short time ago.
Nearly six years after developing the first self-replicating life form with a chemically created genome, scientists at the J. Craig Venter Institute in La Jolla have cut that bacterium’s genome nearly in half. The result is a creature with a smaller genome than has ever been found in nature.
Best Pharma Brands, a global study, identifies the biopharma companies that are addressing healthcare professionals’ (HCPs), payers’, and policy makers’ needs. The study examines what value means to HCPs and illustrates the influence the corporate brand has in conveying that value. It reveals how leading companies are beginning to deliver on what matters to HCPs.
Johns Hopkins Medicine has performed the nation’s first liver and kidney transplants from a donor infected with HIV to recipients also infected with the virus, a triumph for one of the transplant surgeons, who fought for six years for federal approval of the life-saving surgery.
As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to use whole genome sequencing at a Kids First-supported sequencing center to elucidate the genetic contribution to childhood cancers, and to investigate the genetic etiology of structural birth defects. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.
Johns Hopkins is setting its sights on an end to cancer with its new Bloomberg-Kimmel Institute for Cancer Immunotherapy.
When someone with a high fever walks into a rural African clinic, diagnosis could be murky. The symptoms could be those of dengue, Ebola, West Nile disease, malaria or flu, and blood work results from distant labs, if available, often takes days. Now a handful of researchers are separately working on inexpensive, paper-based diagnostic tests that accurately pinpoint the cause of a disease in minutes and could speed up treatment and prevent its spread. The lack of funds and commercial partners however, means most might languish in labs.
Johns Hopkins is launching an immunotherapy center for cancer research with a $125 million gift from longtime Hopkins donors Michael R. Bloomberg and Sidney Kimmel, along with other donors.
GlaxoSmithKline Pharmaceuticals Ltd is looking at launching two or three combination vaccines in India in the near future, to address a host of paediatric disease. The company is also organising programmes to spread awareness about the need of vaccination among public.
Gaithersburg cell modification technology firm MaxCyte Inc. is expected to go public on the London Stock Exchange Tuesday morning.
MaxCyte, which will trade under the ticker symbol MXCT, is seeking to raise between $14 million and $15 million, said CEO and President Doug Doerfler.
